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AbstrAct
Background Renal transplant recipients (RTRs) exhibit 
increased vascular stiffness and calcification; these 
parameters are associated with increased cardiovascular 
risk. Activity of endogenous calcification inhibitors such 
as matrix gla protein (MGP) is dependent on vitamin K. 
RTRs commonly have subclinical vitamin K deficiency. 
The Vitamin K in kidney Transplant Organ Recipients: 
Investigating vEssel Stiffness (ViKTORIES) study assesses 
whether vitamin K supplementation reduces vascular 
stiffness and calcification in a diverse population of RTR.
Methods and analysis ViKTORIES (ISRCTN22012044) 
is a single- centre, phase II, parallel- group, randomised, 
double- blind, placebo- controlled trial of the effect 
of vitamin K supplementation in 90 prevalent RTR. 
Participants are eligible if they have a functioning renal 
transplant for >1 year. Those on warfarin, with atrial 
fibrillation, estimated glomerular filtration rate <15 mL/
min/1.73 m2 or contraindications to MRI are excluded. 
Treatment is with vitamin K (menadiol diphosphate) 5 
mg three times per week for 1 year or matching placebo. 
All participants have primary and secondary endpoint 
measures at 0 and 12 months. The primary endpoint is 
ascending aortic distensibility on cardiac MR imaging. 
Secondary endpoints include vascular calcification 
(coronary artery calcium score by CT), cardiac structure 
and function on MR, carotid- femoral pulse wave 
velocity, serum uncarboxylated MGP, transplant function, 
proteinuria and quality of life. The study is powered to 
detect 1.0×10–3 mm Hg-1 improvement in ascending aortic 
distensibility in the vitamin K group relative to placebo at 
12 months. Analyses will be conducted as between- group 
differences at 12 months by intention to treat.
Discussion This trial may identify a novel, inexpensive 
and low- risk treatment to improve surrogate markers of 
cardiovascular risk in RTR.
BaCkgrounD
Cardiovascular disease (CVD) is the leading 
cause of premature mortality in patients with 
renal disease.1 For patients with end- stage 
kidney disease (ESKD), renal transplantation 
affords the greatest benefit in terms of CVD 
risk reduction compared with dialysis, but 
renal transplant recipients (RTR) remain at 
3–4 times elevated CVD risk compared with 
the general population2 and die prematurely 
from CVD, often with a functioning kidney 
transplant.3 Among patients with advanced 
chronic kidney disease (CKD), vascular stiff-
ness and calcification are common,4 linked 
and associated with cardiovascular events 
and mortality.5–7 Standard secondary preven-
tion therapies—such as maintenance blood 
pressure targets and cholesterol- lowering 
agents—are recommended in the transplant 
population,8 however, these strategies are 
inadequate in RTR with non- traditional risk 
factors for CVD.9 10
The development and progression of 
vascular stiffness and calcification are heavily 
influenced by the activity of calcification 
inhibitors,11 such as matrix gla protein 
(MGP), osteocalcin and Gla- rich protein.12 
These proteins are reliant on conversion to 
their active forms by a vitamin K- dependent 
post- translational modification (gamma 
carboxylation). Among RTR, vitamin K 
intake is inadequate13 and subclinical defi-
ciency is prevalent and associated with CVD 
and mortality.14 By optimising the function 
of vitamin K- dependent calcification inhibi-
tors, vitamin K supplementation may offer a 
cost- effective and low- risk treatment option 
to reduce long- term cardiovascular risk and 
mortality and maximise organ preservation 
in RTR. By testing vitamin K supplements at 
supraphysiological dose, we may nullify the 
confounder that patients with diet rich in 
vitamin K are ‘healthier’ overall, with lower 
CVD risk and better outcomes.15
Trials of vitamin K to improve vascular stiff-
ness and calcification show promising results 
in various populations.16 We designed the 
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Figure 1 ViKTORIES study design and timetable. ViKTORIES, Vitamin K in kidney Transplant Organ Recipients: Investigating 
vEssel Stiffness.
Vitamin K in kidney Transplant Organ Recipients: Inves-
tigating vEssel Stiffness (ViKTORIES trial) to investigate 
the hypothesis that vitamin K supplementation improves 
vascular stiffness and calcification over 1 year in prevalent 
RTR.
MethoDs anD analysis
trial design and participants
The ViKTORIES trial is a single- centre, phase II, parallel- 
group, randomised, double- blind, placebo- controlled 
trial in prevalent RTRs (figure 1). We enrol adult partici-
pants (18 years or over with a functioning renal transplant 
implanted >12 months and with estimated glomerular 
filtration rate (eGFR—measured by the chronic kidney 
disease epidemiology collaboration (CKD- EPI) equa-
tion17) >15 mL/min/1.73 m2. Patients are excluded if 
they meet any of the following criteria: known permanent 
or paroxysmal atrial fibrillation, concurrent warfarin use, 
taking vitamin K or indication for vitamin K, allergy to 
gelatine, lactose or cellulose (constituent ingredients of 
the capsules or packing materials used to make the inter-
ventions), breast feeding or of childbearing potential, 
known glucose-6- phosphate dehydrogenase (G6PD) defi-
ciency, life expectancy <12 months, standard contraindi-
cations to MRI18 or inability to provide written informed 
consent in English.
interventions
Menadiol diphosphate is a synthetic, water- soluble form 
of vitamin K, licensed for use in the UK for treatment of 
haemorrhage associated with deficiency of vitamin K- de-
pendent clotting factors. This form of vitamin K is likely 
to be better absorbed than standard fat- soluble forms in 
those with malabsorption syndromes. Using this form of 
vitamin K facilitates production of a matching placebo, 
in contrast to other licensed, liquid forms of vitamin K 
(phylloquinone).
Interventions—either 5 mg menadiol diphosphate 
or matching placebo—are administered orally three 
times per week (Monday, Wednesday and Friday) for 1 
year. This dose of menadiol diphosphate was selected to 
ensure excess vitamin K was present for use as cofactor 
for vitamin K- dependent carboxylation. Size 4 gelatine 
capsules are prepared containing menadiol diphosphate 
5 mg and packed with microcrystalline cellulose Ph. 
Eur. (Tayside Pharmaceuticals, Dundee, UK). Identical 
capsules are packed with microcrystalline cellulose Ph. 
Eur. as placebo.
Menadiol diphosphate was originally sourced from 
licensed 10 mg tablets (Alliance Pharmaceuticals, Chip-
penham, UK) which were crushed and packed into 
capsules at the desired 5 mg dose. Due to a supply issue 
of licensed menadiol tablets after study commence-
ment, capsules are now manufactured using 5 mg mena-
diol diphosphate United States Pharmacopeia (USP) 
with lactose as packing material but all other manufac-
turing the same. No interruption to dose or supply of 
dispensed study medication occurred due to this change 
of preparation.
randomisation sequence generation
A computer- generated code list is provided by Sealed 
Envelope (Sealed Envelope, London, UK) in a password- 
protected file to drug manufacturer (Tayside Pharma-
ceuticals) to produce identical, sequentially numbered 
bottles containing either vitamin K or placebo. The code 
list is organised in random permuted blocks to facilitate 
unstratified 1:1 allocation ratio.
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allocation concealment mechanism
Randomisation is conducted by study investigators or 
trained research nurses using a custom- built, password- 
protected online system, created and maintained by 
Sealed Envelope.
implementation
Local investigators (JSL, ER, PBM and AGJ) recruit 
participants from routine outpatient transplant clinic 
appointments in National Health Service (NHS) Greater 
Glasgow and Clyde (Scotland, UK) and enrol participants 
into the study, including obtaining informed consent and 
randomising according to methods detailed above.
Blinding
Local investigators, research nurses, pharmacy staff and 
participants are blinded to treatment allocation by use 
of numbered but otherwise identical medication bottles. 
Investigations including laboratory blood and urine 
samples, pulse wave velocity measurements, quality of life 
questionnaires are conducted by blinded study investi-
gators or laboratory staff. After enrolment in the study, 
participants are given a 5- digit study ID (2- digit site code 
‘01’ followed by 3- digit sequential screening code).
Data capture
A custom- designed electronic case report form is used, 
designed (by JSL) using Castor Electronic Data Capture ( 
www. castoredc. com; Amsterdam, Netherlands).
outcomes
Primary outcome
The primary outcome is between- group difference in 
ascending aortic distensibility at 12 months measured by 
analysis of covariance (ANCOVA), adjusting for covari-
ates of age, duration of ESKD and the baseline value of 
ascending aortic distensibility. Measured by cardiac MRI, 
aortic distensibility is an accurate and highly reproduc-
ible measure of aortic stiffness19 and is an early predictor 
of CVD and mortality.20–22
Secondary outcomes
All secondary outcomes are assessed as between- group 
differences at 12 months by ANCOVA, treating age, 
duration of ESKD and the baseline value of the outcome 
of interest as covariates. Secondary outcome measures 
include the following: coronary artery calcification score 
by non- contrast CT, carotid- femoral pulse wave velocity 
and augmentation index (SphygmoCor XCEL PWA and 
PWV software, AtCor Medical, Australia), MR measures 
of cardiac structure and function (descending aortic 
distensibility, left/right ventricular mass, function and 
strain, T1 and T2 relaxation times), markers of vitamin 
K status: desphospho- uncarboxylated MGP (dp- ucMGP), 
office blood pressure, ECG, bone metabolism and 
turnover (calcium, phosphate, parathyroid hormone, 
25- hydroxyvitamin D), transplant function, protein-
uria and quality of life (EuroQol-5 Dimension-5 level 
instrument23). Several other biomarkers will be tested 
as secondary outcomes if funding allows: calcification 
propensity (T50), elastin degradation products, bone 
metabolism and turnover (1- 25hydrovitamin D, fibro-
blast growth factor-23, osteocalcin, fetuin, bone morpho-
genetic protein, tartrate- resistant acid phosphatase- 5b), 
cardiovascular markers (high- sensitivity troponin, brain 
natriuretic peptide) and endothelial function (asym-
metric dimethylarginine). Additional plasma, serum 
and urine are collected and frozen for future testing 
of unspecified biomarkers (with consent), which may 
include but are not limited to biomarkers of vitamin K 
status (other than dp- ucMGP) and tubulointerstitial 
fibrosis. Participants are asked to keep a food diary for 28 
days for estimation of dietary vitamin K content.
Mr acquisition technique
Participants undergo non- contrast cardiac MR on a 
Siemens Prisma 3T scanner (Siemens Inc, Erlangen, 
Germany) in the research MR facility at the Queen Eliz-
abeth University Hospital, Glasgow. An 18- channel body 
array is used anteriorly with a 32- channel spine array for 
posterior acquisition. Scans are gated by electrocardiog-
raphy. Typical image acquisition sequence is summarised 
in table 1. Illustrative images of selected MRI sequences 
are displayed in figure 2.
Cine imaging of the ascending and descending aorta is 
acquired for measurement of vessel size for distensibility 
measurements, at the level of the right pulmonary artery 
for the ascending aorta and approximately 10 cm above 
the diaphragm for the descending aorta. Typical imaging 
parameters are: field of view (FOV) 340×286 mm, slice 
thickness 7 mm, TR −20.7 ms, TE 1.51 ms, flip angle 50°, 
voxel size 1.33×1.33x7 mm.
Left ventricular (LV) mass and function are assessed 
from balanced steady state free precession cine imaging 
(TrueFISP) in long axis planes (vertical long axis, hori-
zontal long axis and LV outflow tract) then with sequen-
tial short axis LV cine images (7 mm slice thickness, 3 mm 
gap between slices) from the atrioventricular ring to the 
apex. Typical scan parameters are as follows for retrospec-
tively gated TrueFISP 2d (tfi2d) sequence: FOV 340×286 
mm, slice thickness 7 mm with 3 mm gap in short axis 
(SA) stack, repetition time (TR) – 41.4 ms, echo time 
(TE) 1.51 ms, flip angle 50°, voxel size 1.33×1.33 x 7 mm, 
30 calculated phases.
Parametric maps are acquired from three short- axis 
images at the basal, mid and apical segments of the left 
ventricle and tagging from a single short- axis image at 
the mid segment of the left ventricle. A T2 prepared 
sequence, BEAT map turbo flash 2d, was acquired with 
the following typical imaging parameters: FOV 360×288 
mm, slice thickness 8 mm, TR—207 ms, TE 1.3 ms, flip 
angle 12°, voxel size 1.9×1.9 x 8 mm. T2 preparations x3 
are imaged over a 9- heartbeat period with duration 0 ms, 
30 ms, 55 ms and with a 3- heartbeat recovery period.
A motion- corrected 2D BEAT map sequence (tfi2d) 
optimised for heart rate is used to acquire T1 maps. 
Typical imaging parameters are: FOV 360×306 mm, slice 
Open Heart
4 Lees JS, et al. Open Heart 2020;7:e001070. doi:10.1136/openhrt-2019-001070
Table 1 Typical MRI acquisition sequence
Scan type Region MRI sequence type Time
Localiser Thorax Three plane localisers 1 min
Cardiac Two and four- chamber views
Short axis localiser
1 min
Anatomical Thorax Haste in transverse and coronal planes 4 min
Aorta Aorta cine TrueFISP/gradient echo cine 1 min
Orthogonal ascending aorta TrueFISP/gradient echo cine 1 min
Orthogonal descending aorta TrueFISP/gradient echo cine 1 min
Transverse cine and flow ascending aorta TrueFISP cine and flow 5 min
Transverse cine and flow descending aorta TrueFISP cine and flow 5 min
Functional cardiac Horizontal long axis
Vertical long axis
Left ventricular outflow tract
TrueFISP cine 7 mm thick
TrueFISP cine 7 mm thick
TrueFISP cine 7 mm thick
4 min
4 min
4 min
Short axis stack (left ventricle) TrueFISP cine 7 mm thick/3 mm gap 10 min
Myocardium Cardiac (limited) T1 Map x 3 (short axis: basal, mid, apical) 2 min
T2 Map x 3 (short axis: basal, mid, apical) 0.5 min
Tagging (short axis image: mid segment) 0.5 min
Total time 44 min
Figure 2 Illustrative images of MRI scan acquisition. (A) Two- chamber localiser; (B) four- chamber localiser; (C) left ventricular 
short axis localiser; (D) haste in transverse plane; (E) haste in coronal plane; (F) aorta cine; (G) orthogonal ascending aorta; (H) 
orthogonal descending aorta; (I) transverse cine ascending aorta; (J) transverse cine descending aorta; (K) vertical long axis 
cine; (L) horizontal long axis cine; (M) left ventricular outflow tract cine; (N) left ventricular short axis stack cine; (O) T1 map mid 
segment; (P) T2 map mid segment; (Q) left ventricular short axis tagging mid segment.
thickness 8 mm, TR—280 ms, TE 1.12 ms, flip angle 35°, 
TI 180 ms, voxel size 1.4×1.4 x 8mm. Two T1 preparations 
are imaged over an 11- heartbeat period with a starting T1 
time of 100 ms with increment of 80 ms.
Mr image assessment
MR images are analysed for primary and secondary 
endpoints as above using Argus (Siemens Inc, Erlangen, 
Germany) and Cvi42 (Circle Cardiovascular Imaging, 
Calgary AB, Canada) software by an investigator blinded 
to treatment allocation (JSL).
aortic distensibility analysis
Aortic volumes are measured by manually tracing the 
endovascular border of the ascending and descending 
aorta (figure 3A/B). Non- invasive brachial blood 
pressure is recorded simultaneously with capture of cine 
images using a non- ferromagnetic cuff (Philips Expres-
sion MR400 and Expression IP5, MRI Devices, Knares-
borough, UK), and aortic distensibility (mm Hg-1) in 
ascending and descending aorta calculated from the 
following equation21 24 25:
AD=[Maximum aortic volume (mL)]–[Minimum 
aortic volume (mL)]
[Minimum aortic volume (mL)]xPulse Pressure (mm 
Hg)
left/right ventricular mass and function analysis
Endocardial and epicardial borders are outlined at 
end- diastole and end- systole on short axis cine images 
to estimate LV mass and function in standard fashion26 
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Figure 3 A and B: contours drawn around the endovascular border of the ascending aorta (A) for estimation of ascending 
aortic distensibility and descending aorta (B) for assessment of descending aortic distensibility. C and D: endocardial (red) and 
epicardial (green) borders outlined at end- diastole (C) and end- systole (D) on short axis cine images to estimate left ventricular 
mass and function. Papillary muscles excluded from left ventricular mass measurements.
(figure 3C/D). Using body weight and height acquired 
immediately before scanning, the end- systolic and end- 
diastolic volumes and LV mass are indexed to body 
surface area.
strain
Endocardial and epicardial contours are defined as above 
on LV short- axis views, and inferior reference point is 
defined at the insertion point of the right ventricle. LV 
and RV extent, endocardial and epicardial contours are 
defined at end- diastole and end- systole on vertical long 
axis and horizontal long axis views. Three- dimension 
(3D) left and right ventricular strain analysis is conducted 
using dedicated feature- tracking software.
Parametric map analysis
LV contours are defined on raw T1 and T2 images then 
copied onto the colour- enhanced spatially coregis-
tered maps. The anterior right ventricular- septal inser-
tion point is used as a reference, and both T1 and T2 
maps analysed for 16 segments according to the Amer-
ican Heart Association (AHA) model (apex segment 17 
excluded).27 User- defined semiautomated border deline-
ation is used to create AHA regions of interest of similar 
size and shape, taking care not to overlap with other 
tissue interfaces. Relaxation times are measured in each 
of the 16 segments.
Acceptable segments are identified by assessing indi-
vidual segments for susceptibility and motion artefacts. 
Those segments affected by artefact are removed and a 
mean global T1 or T2 time calculated from the remaining 
segments. An average septal T1 or T2 time is calculated 
by using acceptable anteroseptal, inferoseptal and septal 
AHA segments (segment numbers 2, 3, 8, 9 and 14).
intra and interobserver variability
There will be blinded reanalysis of n=20 randomly 
selected datasets, in random order, for intraobserver and 
interobserver variability for all primary and secondary 
MR outcomes above.
Ct image acquisition
Images for coronary artery calcification score are 
obtained using an Aquilion ONE Vision Edition CT 
scanner (Canon Medical Systems, Crawley, UK) in the 
Clinical Research Imaging Facility at the Queen Elizabeth 
University Hospital in Glasgow. Scans are acquired with a 
single heartbeat non- contrast volumetric scan; adaptive 
iterative dose reduction (AIDR) 3D iterative reconstruc-
tion is employed for radiation dose minimisation.
Ct image assessment
Coronary artery calcification (Agatston) score28 is calcu-
lated using Vitrea Advanced Visualisation software 
(Vital Images Inc, Minnetonka, Minnesota, USA) by a 
consultant radiologist with 14 years experience blinded 
to treatment allocation (GHR), excluding segments with 
previous coronary artery stents in situ (figure 4).
statistical considerations
The ViKTORIES study has a statistical analysis plan in 
line with Consolidated Standards of Reporting Trials 
(CONSORT) guidelines. We will analyse differences 
between treatment and placebo groups by intention 
to treat as the primary analysis, and will conduct per- 
protocol analyses as sensitivity analyses. Analysis of 
the primary outcome (between- group difference in 
ascending aortic distensibility at 12 months) will be 
performed by ANCOVA adjusting for age, duration of 
ESKD and baseline values. Secondary analyses will simi-
larly be by between- group ANCOVA, adjusting for age, 
duration of ESKD and baseline values of the variable 
of interest. All prespecified secondary outcomes will be 
reported in study publications. Subgroup analyses will be 
performed in older versus younger participants (age >65 
vs <65 years) by analysing for heterogeneity of treatment 
effect. As a sensitivity analysis, we will perform multiple 
imputation for missing data for the primary outcome if 
the assumption of Missing at Random is met. The number 
and characteristics of serious adverse events (SAE) will be 
summarised as a whole and by study arm. Analyses will be 
conducted using R statistical software package (R V.3.5.3 
or higher).
sample size
Sample size has been determined to detect a 1.0×10–3 
(SD 1.3×10–3) mm Hg-1 improvement in ascending aortic 
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Figure 4 Cross- sectional, non- contrast CT images of the heart. Total coronary calcification score is calculated for each artery 
according to the density and area of calcification (arrows) observed in each artery. The sum of calcification scores in each 
artery gives a total coronary calcium score.
distensibility in the intervention group relative to placebo 
at 12 months: a difference that we have previously shown 
to be associated with clinical difference in survival to 
death or cardiovascular event at 2 years.21 To achieve a 
power of 90% with alpha=0.05 requires 37 patients per 
group (74 in total). We assume a dropout rate of 20% 
over 12 months of follow- up (a conservative estimate 
based on previous studies) and aim to recruit 90 partici-
pants in total.
Follow-up and timetable
The study timetable is illustrated in figure 1. Recruitment 
commenced in September 2017 and all 90 participants 
were recruited and randomised by end June 2018. The 
study will complete when the last participant completes 
the last follow- up visit (estimated by July 2019). Results 
are expected by December 2019.
registration
ViKTORIES was prospectively registered with ISRCTN 
Registry on 26/09/2017 (ISRCTN22012044).
ethics
The study is being conducted in accordance with the 
World Medical Association Declaration of Helsinki 
(1964) and its revisions. The trial was approved by the 
West of Scotland Research Ethics Committee 4 (Ref: 17/
WS/0101 on 22/06/2017) and is sponsored by NHS 
Greater Glasgow and Clyde Research and Development 
Department (Ref: GN16RE696 on 22/09/2017). The 
study follows standard operating procedures of the trial 
Sponsor (https://www. glasgowctu. org/ sops. aspx; NHS 
Greater Glasgow and Clyde, Scotland, UK as part of 
Glasgow Clinical Trials Unit). Trial progress is monitored 
by Sponsor representatives from pharmacy, research and 
development and by the Clinical Trials Manager (KB); 
routine audit was conducted by Sponsor in 2018. An 
annual report is issued to the Research Ethics Committee 
and to the funder (Kidney Research UK). The study 
follows CONSORT guidelines (http://www. consort- state-
ment. org).
safety considerations
Menadiol diphosphate has few undesirable effects but 
allergic reactions have been known to occur rarely. 
Haemolytic anaemia has occurred rarely and is more 
common in G6PD deficiency; we exclude patients with 
this disorder. Similarly, we exclude patients with aller-
gies to any constituent components of the intervention, 
including gelatine (found in capsules), lactose and cellu-
lose (used as packing materials with menadiol diphos-
phate and as placebo). Patients will have monitoring 
of renal transplant function and immunosuppression 
levels in addition to standard care. All adverse events are 
recorded from the time a participant consents to join the 
study until the last study visit. Participants in this trial are 
expected to have multiple comorbidities and high levels 
of illness. The following are therefore classed as expected 
within this cohort of patients: death or hospitalisation due 
to new cardiovascular event, new diagnosis or treatment 
of cancer, fall or fracture, infection, exacerbation of an 
existing medical condition, deteriorating renal function, 
high or low potassium levels, nausea, vomiting, consti-
pation or diarrhoea; admission for elective or planned 
investigation or treatment. For the purposes of this study, 
only suspected unexpected serious adverse reactions 
are collected in an expedited manner and reported to 
the sponsor via the pharmacovigilance office (within 24 
hours of the site becoming aware of the event). These 
events are determined if they are suspected to be caused 
by the intervention (ie, an unexpected SAE that occurred 
after the initiation of the intervention and without a 
clear alternative explanation) but the events are not in 
keeping with information known about menadiol diphos-
phate. Participants with unresolved adverse events at the 
last study visit will be followed up until resolution or 30 
days (whichever is sooner).
Dissemination plan
Complete trial data will be submitted for presentation 
at an international meeting and will be published in a 
peer- reviewed journal, and shared on social media. After 
publication, ViKTORIES participants will be informed of 
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trials results by letter and the dataset will be contributed 
to the Virtual International Renal and Transplant Trials 
Archive ( www. virt ualt rial sarc hives. org/ virtta).
twitter Jennifer Susan Lees @jennifer_s_lees and Kenneth Mangion @kenneth_
mangion
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